Evidence map›Paper›PMID 40418206›Full record

ArticleJournal of cellular and molecular medicine2025

Exploring the Molecular Mechanism of Hydroxychloroquine Against IgAN Through Network Pharmacology, MD Simulations and Experimental Assessment.

Yuyuan Liu, Jinfang Hu, Jialing Wang, Yanzhe Wang, Gang Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yuyuan LiuDepartment of Nephrology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, Jiangsu, China.
Jinfang HuDepartment of Nephrology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, Jiangsu, China.
Jialing WangDepartment of Nephrology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yanzhe WangDepartment of Nephrology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Gang WuDepartment of Nephrology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, Jiangsu, China.ORCID 0009-0005-7799-6357

Funding

National Natural Science Foundation of China 82300836Science and Technology Program of Suzhou SKY2023206
6 · The paper itself

Abstract

Hydroxychloroquine (HCQ) has recently been reported to be an effective treatment for IgA nephropathy (IgAN); however, the exact mechanism remains elusive. This study aimed to explore the molecular mechanisms of HCQ against IgAN. IgAN-related genes and HCQ target sets were screened from online databases, and a section of them was identified as targets of HCQ against IgAN. In total, 1575 IgAN- related genes, 415 HCQ targets, and 125 targets of HCQ against IgAN were identified. The results of the enrichment analysis showed that the targets of HCQ against IgAN were related to inflammation and immune response related pathways. The PPI network and subnetworks identified prostaglandin-endoperoxide synthase 2 (PTGS2) as the main seed gene. Molecular docking and molecular dynamic (MD) simulations revealed that HCQ could well bind to the PTGS2 protein. Furthermore, clinical data indicated that PTGS2 was overexpressed in patients with IgAN and was negatively correlated with estimated glomerular filtration rate (eGFR). Moreover, consistent with the effect of meloxicam, a PTGS2 inhibitor, HCQ could decrease the expression of PTGS2 and profibrotic proteins in the IgAN cell model. Consequently, HCQ can mediate inflammation and immune response regulation via multiple pathways and targets, among which PTGS2 is probably the key target of HCQ against IgAN.

Indexed as

Glomerulonephritis, IGAHydroxychloroquineMolecular Dynamics SimulationNetwork PharmacologyCyclooxygenase 2HumansMolecular Docking SimulationProtein Interaction MapsCyclooxygenase 2HydroxychloroquinePTGS2 protein, humanhydroxychloroquineIgA nephropathymolecular dynamics simulationnetwork pharmacologyPTGS2

Identifiers

PMID40418206
PMCPMC12105495

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.